Post by Idorsia Pharmaceuticals Ltd

At #ESH2026, Prof. Markus Schlaich presented new analyses from the Phase 3 PRECISION study demonstrating significant and sustained reductions in albuminuria risk in patients with resistant hypertension. Read more in our latest press release: https://bit.ly/idiamr #Hypertension #KidneyHealth #CardiovascularHealth